Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Johnson & Johnson
  6. News
  7. Summary
    JNJ   US4781601046

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00:02 2023-03-31 pm EDT
155.00 USD   +1.02%
03/30Janssen Pharmaceutical - New RYBREVANT Data Showed Long-Term Clinical Response and Safety in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Who Have Failed Prior Platinum-Based Chemotherapy
AQ
03/30Janssen Provides Portfolio Update
AQ
03/29Sector Update: Health Care Stocks Steady Late Wednesday
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about JOHNSON & JOHNSON
03/30Janssen Pharmaceutical - New RYBREVANT Data Showed Long-Term Clinical Response and Safe..
AQ
03/30Janssen Provides Portfolio Update
AQ
03/29UBS Adjusts Johnson & Johnson Price Target to $164 From $175, Maintains Neutral Rating
MT
03/29Johnson & Johnson Unit to Discontinue Respiratory Syncytial Virus Vaccine Program in Ad..
MT
03/23Janssen Pharmaceutical Says Health Canada Authorizes Expanded Use of Imbruvica in Combi..
MT
03/22Talc Plaintiffs Will Press to Reopen Courthouse Doors
PR
03/20The Texas Two-Step Is Alive And Well
AQ
03/20Janssen Pharmaceutical - TREMFYA Real-World Data Analyses Show Greater Treatment Persis..
AQ
03/15Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
BU
03/15Johnson & Johnson Unit Janssen Says Pre-Clinical Results Showed Dengue Candidate Drug D..
MT
03/15Janssen Announces Novel Dengue Antiviral Demonstrates Efficacy in Pre-Clinical Data Pub..
BU
03/15Johnson & Johnson Receives Shareholder Proposal from Mercy Investment Services Inc
CI
03/15Johnson & Johnson Receives Shareholder Proposal from Vermont Pension Investment Commiss..
CI
03/15Johnson & Johnson Receives Shareholder Proposal from Oxfam America Inc
CI
03/15Johnson & Johnson Receives Shareholder Proposal from Hal Scott/The Doris Behr 2012 Irre..
CI
More most relevant news
All news about JOHNSON & JOHNSON
03/30Janssen Pharmaceutical - New RYBREVANT Data Showed Long-Term Clinical Response and Safe..
AQ
03/30Janssen Provides Portfolio Update
AQ
03/29Sector Update: Health Care Stocks Steady Late Wednesday
MT
03/29Sector Update: Health Care Stocks Mixed on Wednesday Afternoon
MT
03/29UBS Adjusts Johnson & Johnson Price Target to $164 From $175, Maintains Neutral Rating
MT
03/29Johnson & Johnson Unit to Discontinue Respiratory Syncytial Virus Vaccine Program in Ad..
MT
03/29STAAR Surgical Appoints Warren Foust as Chief Operating Officer
MT
03/29Virtual Incision Expands Leadership Team as it Prepares for New Market Growth
AQ
03/23Janssen Pharmaceutical Says Health Canada Authorizes Expanded Use of Imbruvica in Combi..
MT
03/22Talc Plaintiffs Will Press to Reopen Courthouse Doors
PR
More news
News in other languages on JOHNSON & JOHNSON
03/29Mise à jour sectorielle : Les valeurs de la santé restent stable..
03/29Mise à jour sectorielle : les titres du secteur de la santé sont..
03/29J&J : Janssen abandonne son projet de vaccin contre le RSV
03/29Johnson & Johnson Unit interrompt son programme de vaccination des adultes contre le vi..
03/29STAAR Surgical nomme Warren Foust au poste de directeur des opérations
03/23Janssen Pharmaceutical annonce que Santé Canada autorise l'utilisation élargie d'Imbruv..
03/17J&J : résultats positifs pour Tremfya contre le psoriasis
03/15Janssen, une unité de Johnson & Johnson, déclare que les résultats précliniques montren..
03/15Halozyme Therapeutics réaffirme ses prévisions de recettes pour 2023 après la révocatio..
03/15Johnson & Johnson reçoit une proposition d'actionnaire de Hal Scott/The Doris Behr 2012..
More news
Analyst Recommendations on JOHNSON & JOHNSON
03/29UBS Adjusts Johnson & Johnson Price Target to $164 From $175, Maintains Neutral Rating
MT
03/01Guggenheim Initiates Johnson & Johnson at Neutral With $161 Price Target
MT
01/25Morgan Stanley Adjusts Price Target on Johnson & Johnson to $180 From $176, Maintains E..
MT
01/25Atlantic Equities Adjusts Johnson & Johnson's Price Target to $168 From $160, Keeps Neu..
MT
01/20SVB Securities Adjusts Price Target on Johnson & Johnson to $186 From $194, Maintains O..
MT
More recommendations
Press releases
03/30Janssen Pharmaceutical - New RYBREVANT Data Showed Long-Term Clinical Response and Safe..
AQ
03/30Janssen Provides Portfolio Update
AQ
03/29Virtual Incision Expands Leadership Team as it Prepares for New Market Growth
AQ
03/22Talc Plaintiffs Will Press to Reopen Courthouse Doors
PR
03/20The Texas Two-Step Is Alive And Well
AQ
More press releases
Analysis
J&J CEO Joaquin Duato to take additional role of Chairman
Upcoming event on JOHNSON & JOHNSON
04/18/23Q1 2023 Earnings Call
Upcoming sector events
04/27/23ABBVIE INC. : Q1 2023 Earnings Release (Projected)
04/27/23ELI LILLY AND COMPANY : Q1 2023 Earnings Release
04/27/23MERCK & CO., INC. : Q1 2023 Earnings Release
05/04/23NOVO NORDISK A/S : Q1 2023 Earnings Release
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Other Pharmaceuticals
1 MarketScreener is worth more than 1000 Influencers!
100% Free Registration
fermer